Dingwei Ye
270 Dong'an Road, Xuhui District, Shanghai, China · Fudan University Shanghai Cancer Center, Fudan University · Fudan University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dingwei Ye as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 22:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07777848 · A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).Ractigen Therapeutics. · not yet recruiting · Non-muscle Invasive Bladder Cancer (NMIBC) · principal investigator
- Ph1/Ph2NCT07567521 · A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPCC Ray Therapeutics · recruiting · Prostate Cancer · study chair
- Ph2NCT07497919 · A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile CancerFudan University · recruiting · Penile Cancer · principal investigator
- N/ANCT07024680 · Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCCAstraZeneca · completed · Papillary Renal Cell Carcinoma · principal investigator
- Ph2NCT06738745 · Study of HRS-2189 Combined HRS-5041 in Prostate CancerFudan University · not yet recruiting · Prostate Cancer Metastatic Disease · principal investigator
- Ph1/Ph2NCT06588179 · SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBtFudan University · not yet recruiting · NMIBC · principal investigator
- Ph1NCT06427291 · Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC PatientsFudan University · unknown · Bladder Cancer · principal investigator
- Ph2NCT06405425 · A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial CarcinomaSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Urothelial Carcinoma · principal investigator
- Ph2NCT06354231 · DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUCFudan University · recruiting · Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney · principal investigator
- Ph1NCT06231277 · Phase I Clinical Trial of BH002 in Patients With Advanced Solid TumorsZhuhai Beihai Biotech Co., Ltd · completed · Solid Tumours · principal investigator
- Ph2NCT06222125 · A Study of HB0025 Injection in Patients With Advanced Renal CancerHuabo Biopharm Co., Ltd. · unknown · Renal Cancer · principal investigator
- Ph2NCT06187506 · Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder CancerFudan University · active not recruiting · Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression · principal investigator
- Ph1NCT06182735 · CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell CarcinomaFudan University · unknown · Renal Cell Carcinoma · principal investigator
- Ph1NCT06094777 · A Study of HY-0102 in Patients With Advanced Solid TumorsShanghai YingLi Pharmaceutical Co. Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph1/Ph2NCT06081686 · Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate CancerSinotau Pharmaceutical Group · unknown · Prostate Cancer · principal investigator
- Ph2NCT05965856 · A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Urothelial Carcinoma, Solid Tumor · principal investigator
- Ph1NCT05843305 · A Study of BPI-452080 in Subjects With Solid TumorsBetta Pharmaceuticals Co., Ltd. · unknown · Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease · principal investigator
- Ph2NCT05785039 · A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System TumorsSichuan Baili Pharmaceutical Co., Ltd. · recruiting · Urinary System Tumor, Solid Tumor · principal investigator
- Ph2NCT05775874 · A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUCAbbisko Therapeutics Co, Ltd · unknown · Urothelial Carcinoma · principal investigator
- N/ANCT05670691 · a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy Without BiopsyFudan University · unknown · Prostatic Neoplasms, Prostatectomy, Prostate Biopsy · study director
- Ph2/Ph3NCT05522231 · Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Hutchmed · completed · Advanced Renal Cell Carcinoma · principal investigator
- Ph2NCT05256472 · A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell CarcinomaAkeso · completed · Renal Cell Carcinoma, First-line Treatment · principal investigator
- Ph2NCT05212857 · Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate CancerFudan University · unknown · Prostate Cancer · study chair
- Ph1NCT05099536 · 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors3D Medicines (Beijing) Co., Ltd. · withdrawn · Solid Tumor, Adult · principal investigator
- Ph3NCT04859751 · Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder CancerQilu Pharmaceutical Co., Ltd. · unknown · Non-Muscle Invasive Bladder Cancer · principal investigator
- Ph2NCT04718584 · the Efficacy and Safety of LDP in Patients With Urinary and Male Genital TumorsDragonboat Biopharmaceutical Company Limited · completed · Bladder Cancer, Renal Carcinoma, Advanced Penile Carcinoma · study chair
- Ph3NCT04563936 · Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®Luye Pharma Group Ltd. · completed · Prostate Cancer · principal investigator
- Ph2NCT04498702 · Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG TherapyJiangsu Yahong Meditech Co., Ltd aka Asieris · completed · Non-muscle Invasive Bladder Cancer · principal investigator
- Ph3NCT04490993 · Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) PatientsJiangsu Yahong Meditech Co., Ltd aka Asieris · unknown · Non-muscle Invasive Bladder Cancer · principal investigator
- Ph3NCT03967977 · Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial CarcinomaBeiGene · active not recruiting · Urothelial Carcinoma · principal investigator
- Ph1/Ph2NCT03843918 · A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate CancerLaekna Limited · terminated · Prostate Cancer Metastatic · principal investigator
- Ph2NCT03827837 · Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological TumorsJiangsu HengRui Medicine Co., Ltd. · unknown · Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer · principal investigator
- Ph1/Ph2NCT03741712 · A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPCJiangsu HengRui Medicine Co., Ltd. · terminated · Prostate Cancer, Castration-resistant Prostate Cancer · principal investigator
- Ph3NCT03520478 · A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate CancerJiangsu HengRui Medicine Co., Ltd. · unknown · Prostate Cancer, Hormone-Dependent Prostate Cancer · principal investigator
- Ph1/Ph2NCT03085966 · Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPCShanghai AbelZeta Ltd. · unknown · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph1/Ph2NCT02691975 · A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer PatientsJiangsu HengRui Medicine Co., Ltd. · unknown · Hormone Refractory Prostate Cancer, Metastatic Prostate Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 22:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 22:56 UTC. The ranking covers the 200 most relevant of 131 PubMed records, and a shared surname and initials can bring in a namesake. All 131 on PubMed
- 1,866 citationsRCR 65.3
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.N Engl J Med · 20191,279 citationsRCR 51.3
- Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.N Engl J Med · 2021894 citationsRCR 48.1
- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.N Engl J Med · 2022870 citationsRCR 65.1
- 702 citationsRCR 27.5
- 647 citationsRCR 25.4
- Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.N Engl J Med · 2023459 citationsRCR 38.4
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.J Clin Oncol · 2021455 citationsRCR 26.3
- Gut Microbiome Fermentation Determines the Efficacy of Exercise for Diabetes Prevention.Cell Metab · 2020331 citationsRCR 16.6
- Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.Ann Oncol · 2018214 citationsRCR 6.7